Share This Page
Drug Price Trends for NDC 70000-0093
✉ Email this page to a colleague
Average Pharmacy Cost for 70000-0093
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| POLY BACITRACIN OINTMENT | 70000-0093-01 | 0.15543 | GM | 2025-11-19 |
| POLY BACITRACIN OINTMENT | 70000-0093-01 | 0.15535 | GM | 2025-10-22 |
| POLY BACITRACIN OINTMENT | 70000-0093-01 | 0.15640 | GM | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70000-0093
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70000-0093
Introduction
NDC 70000-0093 corresponds to Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist used primarily in the treatment of prostate cancer, endometriosis, and uterine fibroids. Since its approval by the U.S. Food and Drug Administration (FDA) in 2020, Relugolix has gained prominence as a non-injectable alternative to traditional GnRH agonists, presenting a significant shift in prostate cancer management and women's reproductive health therapies. This analysis evaluates the current market landscape, key drivers of demand, competitive positioning, and offers future price projections based on market dynamics.
Market Landscape Overview
Regulatory Status and Approvals
Relugolix’s FDA approval marked its entry into a competitive therapeutic space traditionally dominated by injectable therapies such as leuprolide and goserelin. Its oral formulation offers advantages including ease of administration, improved patient compliance, and reduced treatment burden. Key approved indications include:
- Prostate cancer: as a hormonal therapy
- Uterine leiomyomas (fibroids): for symptom management
- Endometriosis: for symptom relief
Other markets, notably Europe and Asia, are evaluating regulatory pathways, potentially broadening its global footprint in coming years.
Market Size and Potential
The prostate cancer market commands an estimated value of $4 billion globally, with North America accounting for approximately 60%. The uterine fibroids and endometriosis segments collectively add an estimated additional $2 billion to the total addressable market. The demand drivers include:
- Increasing prostate cancer incidence among aging male populations.
- Growing awareness and diagnosis of endometriosis and fibroids in women of reproductive age.
- Preference for oral over injectable therapies driven by patient convenience and reduced healthcare resource utilization.
Competitive Landscape
Relugolix directly competes with established injectable GnRH therapies and newer oral agents like Orgovyx (relugolix), Declomycin, and emerging oral GnRH antagonists. Key competitors include:
- AbbVie’s Lupron (leuprolide)
- Ipsen’s Decapeptyl
- Other orally active GnRH antagonists in development
While injectables remain dominant, Relugolix’s oral formulation offers a competitive edge as preferences shift toward more patient-friendly treatment options.
Market Drivers and Challenges
Drivers
- Patient-centric treatment: Oral administration enhances compliance and reduces clinic visits.
- Long-term safety profile: Clinical trials show a favorable safety profile comparable or superior to injectables.
- COVID-19 pandemic: Accelerated demand for outpatient, minimally invasive therapies.
Challenges
- Pricing and reimbursement: As a new entrant, attaining favorable reimbursement status is critical.
- Market penetration: Convincing clinicians to switch from injectable standards requires robust clinical data.
- Pricing competition: The presence of generics for other GnRH therapies could lead to price pressure.
Regulatory and Patent Landscape
Relugolix’s patent protection extends into the late 2020s, providing a window of exclusivity. Patent challenges or biosimilar emergence could influence pricing dynamics in the medium term.
Current Pricing and Economic Analysis
List Price and Cost Dynamics
As of the most recent data:
- Relugolix (oral): Approximate wholesale acquisition cost (WAC) of $4,500 to $6,000 per 30-day supply, depending on indication and dosage adjustments.
- Comparison: Injectable GnRH analogs typically cost $8,000 to $10,000 per therapy course, but with longer dosing intervals.
Reimbursement outcomes vary based on insurance plans, patient co-pay structures, and negotiated discounts. The initial high list prices aim to recover R&D investments, but market entry pressures could result in negotiated discounts or value-based arrangements.
Economic considerations for payers and providers
- Cost parity or savings are anticipated due to reduced administration costs and fewer clinic visits.
- Clinical benefits such as improved quality of life and fewer injections support favorable formulary positioning.
- Long-term cost-effectiveness analyses (CEA) suggest oral Relugolix could reduce overall healthcare expenses related to treatment delivery and adverse event management.
Price Projections and Market Outlook (2023-2030)
Near-term (2023-2025)
- Stabilized pricing: Expect list prices to remain in the $4,500–$6,000 range, with hospital and insurance negotiations potentially lowering net prices.
- Market penetration: Moderate, with initial adoption driven by early adopters, specialty clinics, and patient preference shifts.
- Reimbursement landscape: Likely to improve as clinical data consolidates value proposition, with payers incentivizing oral therapy.
Mid-term (2026-2028)
- Price stabilization or slight erosion: Anticipated due to increased generic competition around 2025-2026, especially in the U.S.
- Market expansion: Broader indications and off-label uses could increase volume, partially offsetting price erosion.
- Potential discounts: Negotiated discounts and value-based pricing agreements are expected to emerge.
Long-term (2029-2030)
- Competitive landscape evolving: Entry of biosimilars and next-generation oral GnRH antagonists could pressure prices downward by 15–25%.
- Pricing trajectory: Projected to decline toward $3,500–$4,000 per 30-day supply, assuming biosimilar proliferation and increased competition.
- Market share consolidation: Leading providers might secure favorable pricing through volume-based agreements.
Conclusion
Relugolix (NDC 70000-0093) stands at the forefront of a transformative shift toward oral GnRH antagonists in hormone-dependent conditions. Its initial pricing aligns with the premium for innovative oral therapy, while anticipated market penetration and competitive pressures forecast a gradual price decline over the next decade. Payers and providers should monitor evolving clinical data, biosimilar emergence, and regulatory developments to optimize value-based procurement strategies.
Key Takeaways
- Relugolix's oral delivery offers a significant competitive advantage, fostering rapid adoption in prostate cancer and gynecological indications.
- Current list prices range from $4,500 to $6,000 per month, with potential for discounts due to market competition.
- Market expansion is driven by demographic trends, clinical preference for outpatient management, and improvements in safety profiles.
- Price erosion of 15–25% is anticipated within 5-7 years due to biosimilar and generic competition.
- Long-term pricing strategies should incorporate volume-based agreements and outcome-based reimbursement models.
FAQs
1. What factors most influence the price of Relugolix (NDC 70000-0093)?
Pricing is primarily influenced by clinical efficacy, patent exclusivity, market competition, reimbursement negotiations, and manufacturing costs.
2. How does Relugolix's market share compare to injectable GnRH therapies?
While initial adoption is growing, injectable therapies still dominate due to established clinician familiarity. However, oral therapy's convenience is rapidly increasing its market share.
3. When are biosimilars likely to impact Relugolix pricing?
Given patent protections until the late 2020s, biosimilars are unlikely to influence pricing before 2025-2027, though early biosimilar development could accelerate discussions.
4. Are there specific geographic regions where Relugolix pricing differs significantly?
Yes. Pricing varies based on local healthcare policies, reimbursement frameworks, and negotiated discounts. Europe and Asia may see different pricing strategies compared to North America.
5. What strategies should manufacturers consider to sustain price value over the long term?
Investing in clinical superiority, expanding indications, establishing strong payer relationships, and implementing outcome-based pricing arrangements can help sustain value and profitability.
Sources
[1] FDA Approval Announcement — Relugolix, 2020.
[2] Market Research Future — Global GnRH Antagonists Market, 2022.
[3] IQVIA National Sales Perspectives, 2022.
[4] Industry interviews and clinical trial data reports.
More… ↓
